Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 20/20 | 0.53 |
| ▸ | CTSD | P07339 | 18/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 14/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL310822 | 0.99 | BACE1 (0.52) | BACE1CTSDCYP3A4 | |
| SCHEMBL310564 | 0.90 | BACE1 (0.43) | BACE1CTSDCYP3A4 | |
| Hydrochloric Acid SCHEMBL309853 | 0.87 | BACE1 (0.63) | BACE1CTSDCYP3A4 | |
| SCHEMBL310014 | 0.83 | BACE1 (0.59) | BACE1CTSDCYP3A4 | |
| SCHEMBL309888 | 0.82 | BACE1 (0.75) | BACE1CTSDCYP3A4 | |
| SCHEMBL308370 | 0.82 | BACE1 (0.75) | BACE1CTSDCYP3A4 | |
| SCHEMBL309727 | 0.82 | BACE1 (0.76) | BACE1CTSDCYP3A4 | |
| SCHEMBL310044 | 0.81 | BACE1 (0.67) | BACE1CTSDCYP3A4 | |
| SCHEMBL309403 | 0.81 | BACE1 (0.75) | BACE1CTSDCYP3A4 | |
| SCHEMBL309408 | 0.80 | BACE1 (0.61) | BACE1CTSDCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093406-B2 | Cyclic sulfones with aminobenzyl substitution useful as BACE inhibitors | NOVARTIS AG (CH) | 2012-01-10 | — | — | US | claimed |
| US-20100056490-A1 | Cyclic sulfones with aminobenzyl substitution useful as BACE inhibitors | NOVARTIS AG (CH) | 2010-03-04 | — | — | US | claimed |
| US-8093406-B2 | Cyclic sulfones with aminobenzyl substitution useful as BACE inhibitors | NOVARTIS AG (CH) | 2012-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056490-A1 | Cyclic sulfones with aminobenzyl substitution useful as BACE inhibitors | BACE2, BACE1, APP | BACE1 2/4885CTSD 33/4885CYP3A4 816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.